報價延遲最少15分鐘:2025/02/23 08:48 EST
|
|
|
|
|
||||||||||||
|
|
|
|
|
13.35 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
64.34/74.50
|
|
企業價值
17.19B
|
| 資產負債 |
|
每股賬面淨值
4.39
|
| 現金流量 |
|
現金流量率
0.04
|
| 損益表 |
|
收益
279.16B
|
|
每股收益
3.85
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/02/23 08:48 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly half of its generics sales, and it services India (about 20% of its generics sales), Russia (10%), and certain European and Latin American countries. Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries. |